Clinical Evidence
The latest research on Mirragen® and how effective it can be on a variety of wounds.
Multicenter Randomized Controlled Trial
Study comparing diabetic ulcers between SOC and Mirragen. After two weeks of screening, patients are randomized for 12 week treatment. For this patient population, Mirragen had the greatest impact during first 4 weeks of treatment.1
79.4% vs. 36.5%
Mirragen doubled the SOC (Standard of Care) in wound area reduction (79.4% vs 36.5%)
2.8x
Mirragen increased healing rate 2.8x vs. SOC
0 Infection
SOC had 5 patients withdrawn due to infection, Mirragen had 0 infections.
In an RCT, investigators concluded that angiogenesis in the Mirragen-treated group was “probably rapid because wound area reduction on average is high over the first week”.1
Weekly percentage wound area reduction by treatment group (From Armstrong et al. 2021, Figure 4).
Lower risk of infection relative to tissue-based products
Pathogen Interaction with Collagen-Based Products:
Many gram-positive pathogens found in diabetic foot ulcers, such as Staphylococcus aureus, Enterococcus faecalis, and Streptococcus equi, can bind to collagen using collagen-binding adhesins.2,3,4
Sources and Vulnerability of Collagen:
Collagen can be extracted from various sources such as porcine, bovine, avian, and piscine tissues. Despite its useful properties, crude natural collagen can be easily colonized and degraded by bacteria and fungi.5
Versatile Form Factor
1 Armstrong DG, Orgill DP, Galiano RD, et al. A multi-centre, single-blinded randomized controlled clinical trial evaluating the effect of resorbable glass fibre matrix in the treatment of diabetic foot ulcers. Int Wound J. 2021;1-11.
2 Lannergafird, J., Frykberg, L., & Guss, B. (2003). CNE, a collagen-binding protein of Streptococcus equi. Department of Microbiology, Swedish University of Agricultural Sciences, P.O. Box 7025, 750 07 Uppsala, Sweden. Accepted 19 March 2003, First published online 8 April 2003.
3 Patti JM, Boles JO, Hook M. Identification and Biochemical Characterization of the Ligand Binding Domain of the Collagen Adhesin from Staphylococcus aureus. Institute of Biosciences and Technology, Center for Extracellular Matrix Biology, Texas A&M University, Houston, Texas 77030. Received June 1, 1993; Revised Manuscript Received August 10, 1993.
4 Rich, R. L., Kreikemeyer, B., Owens, R. T., LaBrenz, S., Narayana, S. V. L., Weinstock, G. M., Murray, B. E., & Ho¨o¨k, M. (1999). Ace Is a Collagen-binding MSCRAMM from Enterococcus faecalis. Received for publication, March 30, 1999, and in revised form, May 6, 1999.
5 Warowicka, A., Kościński, M., Waszczyk, M. et al. Berberine and its derivatives in collagen matrices as antimicrobial agents. MRS Communications 12, 336–342 (2022). https://doi.
org/10.1557/s43579-022-00181-w